摘要
目的探讨血清中内皮细胞特异性因子1(ESM1),Sushi重复含有蛋白质X连接2(SRPX2),糖类抗原125(CA125)联合检测对早期结直肠癌的诊断价值。方法选取早期结直肠癌患者60例为早期组,结直肠良性疾病患者60例为良性组,同时选取体检健康者60例为对照组,检测3组人员血清中ESM1、SRPX2、CA125的表达量。用ROC曲线下面积分析ESM1、SRPX2、CA125对早期结直肠癌的临床诊断价值。结果早期结直肠癌患者血清中ESM1、SRPX2、CA125的表达量均高于结直肠良性疾病患者和体检健康者,差异有统计学意义(P<0.05);单向诊断早期结直肠癌患者与结直肠良性疾病患者ESM1,SRPX2,CA125的灵敏度分别为80%、83%、83%,特异度分别为90%、83%、80%;单向诊断早期结直肠癌患者与体检健康者ESM1、SRPX2、CA125的灵敏度分别为90%、80%、87%,特异度分别为90%、93%、87%;ESM1、SRPX2、CA125联合检测对早期结直肠癌的诊断的灵敏度为86.67%,特异度为88.33%,准确度为87.78%。结论ESM1,SRPX2,CA125诊断早期结直肠癌的临界值分别为30.2、127.4、26.35 ng/mL。ESM1、SRPX2、CA125可作为联合诊断早期结直肠癌的潜在标志物,联合检测可以提高早期结直肠癌与良性病患者及健康患者鉴别诊断能力。
Objective To investigate the diagnostic value of serum endothelial cell specific molecule 1(ESM1),Sushi duplicate protein X-linked 2(SRPX2)and carbohydrate antigen 125(CA125)in early colorectal cancer.Methods A total of 60 patients with early colorectal cancer and 60 patients with benign colorectal diseases were selected as the early group and 60 healthy people as the control group.The expression of ESM1,SRPX2 and CA125 in the serum of the three groups were detected.The clinical diagnostic value of ESM1,SRPX2 and CA125 in early colorectal cancer was analyzed by the area under ROC curve.Results The levels of ESM1,SRPX2 and CA125 in serum of patients with early colorectal cancer were higher than those of patients with benign colorectal diseases and healthy persons(P<0.05).The sensitivity of ESM1,SRPX2 and CA125 in one-way diagnosis of early colorectal cancer and patients with benign colorectal diseases were 80%,83%and 83%,respectively.The sensitivity,specificity and specificity of ESM1,SRPX2 and CA125 were 90%,80%,87%and 90%,93%and 87%respectively for one-way diagnosis of early colorectal cancer and health check-ups.The sensitivity,specificity and accuracy of ESM1,SRPX2 and CA125 in combination for early colorectal cancer diagnosis were 86.67%,88.33%and 87.78%,respectively.Conclusion The critical values of ESM1,SRPX2 and CA125 in the diagnosis of early colorectal cancer are 30.20 ng/mL,127.40 ng/mL and 26.35 ng/mL,respectively.ESM1,SRPX2 and CA125 can be used as potential markers for the combined diagnosis of early colorectal cancer.Combined detection can improve the ability of differential diagnosis between early colorectal cancer and benign diseases and healthy patients.
作者
葛仁美
董业峰
季小忠
洪建军
GE Renmei;DONG Yefeng;JI Xiaozhong;HONG Jianjun(Department of Clinical Laboratory,Hai′an People′s Hospital,Nantong,Jiangsu 226600,China;Department of Western Medicine,Nantong Health Vocational and Technical School,Nantong,Jiangsu 226600,China)
出处
《国际检验医学杂志》
CAS
2019年第20期2538-2541,共4页
International Journal of Laboratory Medicine